Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 19;22(5):433-438.
doi: 10.20892/j.issn.2095-3941.2025.0065.

Advances in the treatment of metastatic prostate cancer in China

Baojun Wang  1 , Zhenhua Liu  2 , Luyao Yang  2 , Xu Zhang  1
Affiliations
Editorial

Advances in the treatment of metastatic prostate cancer in China

Baojun Wang et al. Cancer Biol Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Zhenhua Liu and Luyao Yang are employed by MSD China. The other authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Novel AR axis-directed therapy for the treatment of metastatic prostate cancer. Mechanism underlying androgen synthesis pathway inhibition (e.g., abiraterone and MK-5684) and AR-targeted mechanisms inhibit AR function by blocking (1) agonist binding, (2) nuclear translocation, and/or (3) DNA binding, and thus transcription of AR (e.g., enzalutamide, darolutamide, and rezvilutamide). Alternative therapeutic options include AR PROTAC degraders via a ubiquitin/E3 ligase system or AR-V7 antagonists. Castration resistance can develop through several AR-dependent and -independent processes, including AR mutations that enable non-androgenic hormonal activation. AR, androgen receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. - PubMed
    1. He H, Liang L, Han D, Xu F, Lyu J. Different trends in the incidence and mortality rates of prostate cancer between China and the USA: a joinpoint and age-period-cohort analysis. Front Med (Lausanne) 2022;9:824464. - PMC - PubMed
    1. American Cancer Society. Survival Rates for Prostate Cancer. 2025. Available from: https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-....
    1. Chen K, Jiang K, Tang L, Chen X, Hu J, Sun F. Analysis of clinical trials on therapies for prostate cancer in mainland China and globally from 2010 to 2020. Front Oncol. 2021;11:647110. - PMC - PubMed
    1. Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23:1249–60. - PubMed

Publication types

Grants and funding

LinkOut - more resources